For Biopharma
Unlock Multiomic Insights From a Single Blood Draw
Oncology trials need more than mutation detection. CellSight™ DNA gives biopharma partners real-time tumor biology from whole circulating tumor cells, with high-resolution genomic and phenotypic profiling from one noninvasive sample.
A Smarter Liquid Biopsy for Translational Research
Most liquid biopsies rely on fragmented ctDNA. CellSight™ captures intact tumor cells for deeper analysis, keeping spatial and molecular context that a mutation list cannot carry.
- Genomic profiling: 500+ genes, MSI and TMB
- Phenotypic analysis via protein markers
- Future readiness for RNA expression and fusion detection
Applications for Drug Development
Patient Stratification
For targeted and immunotherapy programs.
Pharmacodynamic Monitoring
Track resistance mutations as they emerge.
Biomarker Discovery
Rare or emerging genomic subtypes.
Tumor Evolution Tracking
Real-time changes across time points.
Key Advantages for Trials
- Noninvasive, repeatable sampling that supports longitudinal data capture
- Higher specificity compared with ctDNA-only assays
- 10 to 14 day turnaround for clinical or exploratory endpoints
- Flexible sample integration into multi-arm or umbrella trial designs
Fit for Precision Oncology
- Solid tumor basket trials
- Immunotherapy and combination strategies
- ADCs, CDx development and real-time resistance surveillance
- Trials with tissue-limited or hard-to-biopsy populations
Partner With CCDx
Tailored solutions for your program.
Trial Integration
Logistics, kits and site support.
Data-Sharing Pipelines
Structured delivery to your data environment.
Custom Biomarker Development
Assays built around your target.
Joint Publication
Co-authored evidence generation.
Let's collaborate to accelerate the future of precision oncology.